Another ongoing clinical trial is also testing MK-2206 in combination with bicalutamide in high-risk prostate cancer patients post-surgery, radiotherapy or cryoablation (NCT01251861), and two structurally similar AKT inhibitors, uprosertib (GSK2141795) and afuresertib (GSK2110183), are also being tested clinically. The gene discussed is AKT1; the disease is prostate carcinoma.